前列腺癌组织中GCDFP15、Calponin表达与患者临床病理特征和预后的关系  

Relationship between GCDFP15, Calponin Expression in Prostate Cancer Tissue and Clinicopathological Characteristics and Prognosis of Patients

作　　者：雷玉 杨代俊 LEI Yu;YANG Daijun(Qianjiang Central Hospital,Qianjiang 433100,China;不详)

机构地区：[1]潜江市中心医院,湖北潜江433100

出　　处：《中外医学研究》2023年第4期64-68,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨前列腺癌组织中巨囊性病液体蛋白15(GCDFP15)、类肌钙蛋白(Calponin)表达与患者临床病理特征和预后的关系。方法:选取2017年3月—2019年3月潜江市中心医院行前列腺根治术的102例前列腺癌患者作为前列腺癌组,另选同期行经尿道前列腺电切术的55例良性前列腺增生患者作为前列腺增生组。采用免疫组化法检测两组前列腺组织中GCDFP15和Calponin表达情况。通过单因素分析GCDFP15、Calponin表达与前列腺癌患者临床病理特征的关系,采用多因素Cox回归分析影响前列腺癌患者预后的危险因素。结果:前列腺癌组的GCDFP15阳性率为79.41%,高于前列腺增生组的1.82%,Calponin阴性率为75.49%,高于前列腺增生组的0(P<0.05)。临床分期为T3和T4期、Gleason≥7分、远处转移、淋巴结转移、术前前列腺特异抗原(PSA)≥20 ng/mL前列腺癌患者的GCDFP15阳性率、Calponin阴性率分别高于T1和T2期、Gleason<7分、无远处转移、无淋巴结转移、术前PSA<20 ng/mL的前列腺癌患者(P<0.05)。GCDFP15阴性表达患者3年生存率为80.95%,高于阳性表达患者的50.62%(P<0.05),Calponin阳性表达患者3年生存率为84.00%,高于阴性表达患者的48.05%(P<0.05)。单因素分析显示,不同Gleason评分、远处转移、淋巴结转移、术前PSA水平的前列腺癌患者3年生存率比较差异有统计学意义(P<0.05)。多因素分析显示,Gleason≥7分、有淋巴结转移、术前PSA水平≥20 ng/mL、GCDFP15阳性表达、Calponin阴性表达是影响前列腺癌患者预后的危险因素(P<0.05)。结论:GCDFP15、Calponin表达异常与前列腺癌的病情进展、预后有关,GCDFP15阳性和Calponin阴性表达能够作为前列腺癌预后评估的生物学指标。Objective: To explore the relationship between gross cystic disease fluid protein 15(GCDFP15), Calponin expression in prostate cancer tissue and clinicopathological characteristics and prognosis of patients. Method: A total of 102 patients with prostate cancer who underwent radical prostatectomy in Qianjiang Central Hospital from March 2017 to March 2019 were selected as the prostate cancer group, and 55 patients with benign prostatic hyperplasia who underwent transurethral resection of prostate at the same time were selected as the prostate hyperplasia group. The expression of GCDFP15 and Calponin in prostate tissues of the two groups was detected by immunohistochemistry. By single factor analysis of the relationship between GCDFP15, Calponin expression and clinicopathological characteristics of prostate cancer patients, multivariate Cox regression analysis was used to analyze the risk factors affecting the prognosis of prostate cancer patients. Result: The positive rate of GCDFP15 in prostate cancer group was 79.41%, which was higher than 1.82%in prostatic hyperplasia group, and the negative rate of Calponin was 75.49%, which was higher than 0 in prostatic hyperplasia group(P<0.05). The positive rate of GCDFP15 and the negative rate of Calponin in prostate cancer patients with clinical stage of T3 and T4,Gleason ≥7 points, distant metastasis, lymph node metastasis, and preoperative prostate specific antigen(PSA) ≥20 ng/mL were higher than those in prostate cancer patients with clinical stage of T1 and T2, Gleason <7 points, no distant metastasis, no lymph node metastasis,and preoperative PSA <20 ng/mL(P<0.05). The 3 year survival rate of patients with negative expression of GCDFP15 was 80.95%, which was higher than 50.62% of patients with positive expression of GCDFP15(P<0.05), and the 3 year survival rate of patients with positive expression of Calponin was 84.00%, which was higher than 48.05% of patients with negative expression of GCDFP15(P<0.05). Univariate analysis showed that there were statistically

关 键 词：前列腺癌 巨囊性病液体蛋白15 类肌钙蛋白 预后 

分 类 号：R737.25[医药卫生—肿瘤]